Hybridoma Development
SDI develops new monoclonal antibodies using two technologies:
Conventional Immunization Technology
This traditional approach to mouse immunization is used when the peptide or protein antigen already exists. Three groups of five mice each are immunized. Dose of antigen and strain of mouse are varied. Pre-immune and immune sera are evaluated by SDI. The screening data and the sera are sent to you for further evaluation. Mice with the immune response are used for somatic cell fusion. Candidate monoclonal antibodies are screened at SDI. The data and the hybridoma culture supernatants are sent to you for further evaluation. Hybridomas secreting monoclonal antibodies with the best performance are cloned to increase the probability of monoclonality.
GENOMIC ANTIBODY TECHNOLOGY™ (GAT)
Using this proprietary technology, immunization of mice for the development of monoclonal antibodies can begin when the sequence of the protein antigen is known. You may have determined the sequence in your laboratory or you may have taken the sequence from public sources. The physical peptide or protein antigen is not required. You provide only the protein sequence information of the protein antigen. We build a plasmid containing sequence information from your protein and transfer the plasmid into the host animals. The immunogen is expressed in vivo where it is immediately recognized by the immune system. Pre-immune and immune sera are evaluated by SDI using protein we express in the laboratory. Data from screening of sera and hybridoma culture supernatant as well as samples of each are transferred to you for further evaluation.
To place an order for Hybridoma Development using conventional immunization technology or using Genomic Antibody Technology™, click here.